CLOVClover Health Investments, Corp.
Price
+39%1YEnd-of-day closes, not the intraday tick.
(1)Represents full year 2025 Benefits expense ratio (“BER”) for Clover Health, as well as most recent results of other public companies with “Traditional MA Plan” approaches that have reported results as of the time of this publication. BER is a non-GAAP financial measure. We calculate our BER by taking the total of Insurance net medical expenses incurred and quality improvements, and dividing that total by premiums earned on a net basis, in a given period.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Business segments
Q2 2025 · $32.4MThe company’s own SEC segment disclosure.
- Insurance$16.2M50%
- Insurance$16.2M50%
Clover Health Investments, Corp. (CLOV) reported revenue of $759M in Q3 2026 (quarter ended Sep 30, 2026), up 53% from the same quarter a year earlier. That came with net income of $6.4M (0.8% of revenue). For the full year FY2025, revenue was $1.92B (+40% year on year) with a net loss of $86M. Its largest segment in Q2 2025 (quarter ended Jun 30, 2025) was Insurance at $16M, 50.0% of the disclosed total, just ahead of Insurance at 50.0%. The next results filing is expected around Feb 3, 2027, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Nov 4, 2026On November 2, 2026, the Board of Directors of the Company appointed Joseph Clay Thornton, age 37, the Company’s Interim Chief Financial Officer and principal financial officer, to serve as the Company’s Chief Financial Officer on a permanent basis, and appointed Joseph Frank Oldakowski, age 44, the Company’s Vice …Earnings release · Form 8-K
- Oct 9, 2026Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027.Regulation FD disclosure · press release
- Sep 25, 2026On September 22, 2026, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Senator Robert G. Torricelli to serve as a Class I director of the Board and Dr. Brian J. Miller, M.D., M.B.A., M.P.H. to serve as a Class III director of the Board.Director or officer change · Form 8-K/A
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Healthcare
The closest names by size in the same sector